Trial Profile
A retrospective trial to assess second-line or greater therapy with doxorubicin + trastuzumab in patients with metastatic, HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Doxorubicin
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Apr 2015 New trial record